April 7, 2017 / 2:52 PM / 3 months ago

BRIEF-FDA approves two of Gilead's hepatitis C drugs for pediatric patients

1 Min Read

April 7 (Reuters) - Gilead Sciences Inc :

* U.S. FDA approves new indications for Harvoni and Sovaldi in pediatric patients 12 years and older with chronic hepatitis C infection

* Harvoni, Sovaldi each have boxed warning in their respective product labels

* Boxed warning for the two drugs relate to risk of hepatitis B virus reactivation in HCV/HBV co-infected patients Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below